产品描述信息
NR-56475??SARS-Related Coronavirus 2, Isolate hCoV-19/USA/HI-CDC-4359259-001/2021 (Lineage B.1.1.529; Omicron Variant)(Viruses)|SARS-Related Coronavirus 2|Isolate hCoV-19/USA/HI-CDC-4359259-001/2021 (Lineage B.1.1.529; Omicron Variant)|-60°C or colder|CDCAcknowledgment for publications should read “The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/USA/HI-CDC-4359259-001/2021 (Lineage B.1.1.529; Omicron Variant), NR-56475, contributed by Centers for Disease Control.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. Due to the high volume of orders, NIAID will prioritize shipments.
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/HI-CDC-4359259-001/2021 was collected on November 27, 2021, in Hawaii, USA.
Note: Genome sequence information is provided on the Certificate of Analysis and includes an analysis of all sequence variations observed for each lot.
Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/HI-CDC-4359259-001/2021 is assigned lineage B.1.1.529 (Pango v.3.1.17 2022-01-05), and GISIAD clade GRA using Phylogenetic Assignment of Named Global Outbreak lineages (PANGO) tool. The complete genome of the clinical isolate of SARS-CoV-2, hCoV-19/USA/HI-CDC-4359259-001/2021 has been sequenced (GISAID: EPI_ISL_8690072). The following mutations are present in EPI_ISL_8690072 after two passages in Vero cells: Spike A67V, Spike D614G, Spike D796Y, Spike E484A, Spike G142D, Spike G339D, Spike G446S, Spike G496S, Spike H69del, Spike H655Y, Spike ins214EPE, Spike L212I, Spike L981F, Spike N211del, Spike N440K, Spike N501Y, Spike N679K, Spike N764K, Spike N856K, Spike N969K, Spike P681H, Spike Q493R, Spike Q498R, Spike Q954H, Spike R346K, Spike S371L, Spike S373P, Spike S375F, Spike S477N, Spike T95I, Spike T478K, Spike T547K, Spike V70del, Spike V143del, Spike Y144del, Spike Y145del, E (Envelope) T9I, M (Membrane) A63T, M D3G, M Q19E, N (Nucleocapsid) E31del, N G204R, N P13L, N R32del, N R203K, N S33del, NSP3 (Non-structural protein 3) A1892T, NSP3 K38R, NSP3 L1266I, NSP3 S1265del, NSP4 (Non-structural protein 4) T492I, NSP5 (Non-structural protein 5) P132H, NSP6 (Non-structural protein 6) G107del, NSP6 I189V, NSP6 L105del, NSP6 S106del, NSP12 (Non-structural protein 12) P323L, NSP14 (Non-structural protein 14) I42V. It was labelled as an Omicron variant by the World Health Organization (WHO) (first detected in Botswana/Hong Kong/South Africa).
Note: Two additional mutations, Spike K417N and Spike Y505H, were identified during sequence analysis, but are not annotated on the GISAID website.
Each vial contains approximately 0.1 mL of spin-clarified cell lysate and supernatant from Homo sapiens lung adenocarcinoma epithelial cells (Calu-3) infected with SARS-CoV-2, isolate hCoV-19/USA/HI-CDC-4359259-001/2021. Quality control for this item is pending.